Cormet Post-PMA Study: New Enrollment (PASNew)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00722007
Recruitment Status : Completed
First Posted : July 25, 2008
Last Update Posted : July 6, 2017
Information provided by (Responsible Party):

Brief Summary:
The primary objective of this study is to evaluate the performance of the Cormet Hip Resurfacing implant system in the post-approval environment.

Condition or disease Intervention/treatment Phase
Osteoarthritis Avascular Necrosis Rheumatoid Arthritis Device: Cormet Hip Resurfacing Not Applicable

Detailed Description:
This study tracks the performance of the Cormet Hip Resurfacing system in the post-approval environment to see if there are significant changes in device performance from the pre-market IDE setting as compared to the post-approval setting. Specifically this study will compare the proportion of subjects achieving a Month 24 composite clinical success (CCS) criterion and 24 month cumulative revision rate among the newly enrolled post-approval study subjects to the IDE subjects' performance on CCS as reported in the Pre-Market Application (PMA).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cormet Hip Resurfacing System Post-PMA Study Group (New Enrollment)
Actual Study Start Date : April 24, 2008
Actual Primary Completion Date : April 11, 2014
Actual Study Completion Date : May 12, 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Cormet Hip Resurfacing Post-PMA Group
hip resurfacing
Device: Cormet Hip Resurfacing
Cormet Hip Resurfacing implant
Other Name: Corin Cormet

Primary Outcome Measures :
  1. to compare composite clinical success and revisions in the post approval study to the IDE study [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Harris Hip Score components including total score, pain, function and range of motion [ Time Frame: 24 months ]
  2. device survival [ Time Frame: 24 months ]
  3. device related adverse events [ Time Frame: 24 months ]
  4. radiographic evaluation including radiolucencies, component migration, femoral subsidence and tilt [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patient who meets eligibility criteria consistent with product labeling
  • skeletally mature
  • mentally capable of completing follow-up forms
  • Will be available for follow-up out to 2 years and annually thereafter until the last patient reaches the two-year evaluation
  • Has been deemed a candidate for hip replacement by diagnosis of the investigator
  • consented to participate in the clinical study

Exclusion Criteria:

  • Patient with active or suspected infection in or around the hip joint;
  • Patient with bone stock inadequate to support the device
  • Patient with severe osteopenia
  • Patient with a family history of severe osteoporosis or severe osteopenia;
  • Patient with osteonecrosis or avascular necrosis (AVN) with >50% involvement of the femoral head (regardless of FICAT Grade)
  • Patient with multiple cysts of the femoral head (>1cm)
  • In cases of questionable bone stock, a DEXA scan may be necessary to assess inadequate bone stock.
  • Patient with any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery;
  • Female of child-bearing age due to unknown effects on the fetus of metal ion release.
  • Patient with known moderate or severe renal insufficiency;
  • Patient who is immunosuppressed with diseases such as AIDS or person receiving high doses of corticosteroids;
  • Patient who is severely overweight;
  • Patient with known or suspected metal sensitivity (e.g., jewelry).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00722007

United States, District of Columbia
George Washington University
Washington, D.C., District of Columbia, United States, 20006
United States, Florida
Florida Orthopaedic Institute
Tampa, Florida, United States, 33637
United States, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
United States, New York
Lattimore Orthopaedics P.C.
Rochester, New York, United States, 14620
United States, Oregon
Willamette Orthopedic Group LLC
Salem, Oregon, United States, 97301
United States, Texas
Memorial Bone and Joint Clinic
Houston, Texas, United States, 77043
Sponsors and Collaborators
Study Director: Kathy Trier Corin

Responsible Party: Corin Identifier: NCT00722007     History of Changes
Other Study ID Numbers: Cormet (P050016) New Enroll
First Posted: July 25, 2008    Key Record Dates
Last Update Posted: July 6, 2017
Last Verified: July 2017

Keywords provided by Corin:
hip resurfacing
avascular necrosis
rheumatoid arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Bone Diseases